» Articles » PMID: 32687719

Aflatoxin B1-Induced COX-2 Expression Promotes Mitophagy and Contributes to Lipid Accumulation in Hepatocytes In Vitro and In Vivo

Overview
Journal Int J Toxicol
Publisher Sage Publications
Specialty Toxicology
Date 2020 Jul 21
PMID 32687719
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Aim: Aflatoxin B1 (AFB1) is hepatotoxic. Numerous studies have shown that mitochondria play an essential role in AFB1-induced steatosis. However, the mechanisms of AFB1-induced steatosis via mitochondria are still obscure. The present study aimed to confirm that AFB1 causes hepatocyte steatosis regulated by cyclooxygenase-2 (COX-2)-induced mitophagy, both in vivo and in vitro.

Methods: Adult male C57BL/6 mice were randomly divided into control group with the same volume of peanut oil and exposure group administered 0.6 mg/kg AFB1 once in 2 days for 1 month. HepG2 and Cas9-PTGS2 cells were treated with 5 μM AFB1 for 48 hours. Then, various indicators were evaluated.

Results: Aflatoxin B1 causes liver injury and steatosis with increased alanine aminotransferase, aspartate aminotransferase, total cholesterol, total triglyceride levels in vivo and in vitro, and elevated lipid droplets in HepG2 cells. Cyclooxygenase-2 and mitophagy pathway were induced by AFB1 in both liver tissues and cultured HepG2 cells. Further studies have shown that knockout of COX-2 with the CRISPR/Cas9 system inhibited the AFB1-induced mitophagy and steatosis in HepG2 cells. Also, the inhibition of PTEN-induced putative kinase with RNA interference attenuated the AFB1-induced steatosis.

Conclusions: The results of the current study suggested that AFB1 increases the expression of COX-2, which, in turn, elevates the level of mitophagy, thereby disrupting the normal mitochondrial lipid metabolism and causing steatosis. Thus, this study implies that COX-2 may be a potential target for therapy against AFB1-induced steatosis.

Citing Articles

Biological properties of activated bentonite vs. non-activated bentonite in mice fed an aflatoxin-contaminated diet: a comparative investigation.

Oskoueian F, Hosseini S, Seddighian H, Abdi S, Jalalian Y, Mashhadi Y Mycotoxin Res. 2025; .

PMID: 40029533 DOI: 10.1007/s12550-025-00584-3.


Metabolic disruption by mycotoxins: focus on metabolic endpoints steatosis, adipogenesis and glucose metabolism in vivo and in vitro.

Heikkinen T, Kublbeck J, Rysa J Arch Toxicol. 2025; .

PMID: 39923202 DOI: 10.1007/s00204-025-03957-w.


The impact of small food workshops management regulations on aflatoxin B in home-made peanut oil and the liver function of high-consumption area residents: an interrupted time series study in Guangzhou, China.

Lei J, Li Y, Wang Y, Zhou J, Wu Y, Zhang Y Front Public Health. 2025; 12:1484414.

PMID: 39758209 PMC: 11695283. DOI: 10.3389/fpubh.2024.1484414.


AFB1 Toxicity in Human Food and Animal Feed Consumption: A Review of Experimental Treatments and Preventive Measures.

Pozarska A, Karpiesiuk K, Kozera W, Czarnik U, Dabrowski M, Zielonka L Int J Mol Sci. 2024; 25(10).

PMID: 38791343 PMC: 11121597. DOI: 10.3390/ijms25105305.


AFB1 Triggers Lipid Metabolism Disorders through the PI3K/Akt Pathway and Mediates Apoptosis Leading to Hepatotoxicity.

Wang T, Li X, Liao G, Wang Z, Han X, Gu J Foods. 2024; 13(1).

PMID: 38201191 PMC: 10778638. DOI: 10.3390/foods13010163.